Complete remission of metastatic malignant melanoma after surgery in association with development of systemic vitiligo

Nishitani, Nao; Bito, Toshinori; Ikeda, Tetsuya; Tokura, Y.; Nishigori, Chikako

doi:10.1111/j.1346-8138.2010.00877.x

Cited by 5 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These very remarkable therapeutical approaches, as well as some new successful vaccination protocols offer new hope to patients with melanoma and now they are applied only in patients with metastatic disease [12]. On the other side, it is important to note that immunologically opposite disease, vitiligo, (a dermatological disorder characterized by the loss of melanin, which results in depigmented areas of the skin), appears in many cases of melanoma regression [13,14]. …”

Section: Introductionmentioning

confidence: 99%

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

Đorđić

Matić

Filipovic-Ljeskovic

et al. 2012

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundThe aim of this study was to determine the presence and the intensity of humoral immunity to melanoma-associated antigens: tyrosinase and melanin, in patients with melanoma, in persons with vitiligo and in control healthy people.MethodsThe study involved 63 patients with melanoma and 19 persons with vitiligo. Control group consisted up to 41 healthy volunteers. Mushroom tyrosinase and synthetic melanin were used as the antigens.ResultsELISA test showed significantly (p < 0.0000004 and p < 0.04) lower levels of IgM anti-tyrosinase autoantibodies, in melanoma and vitiligo patients respectively, compared to controls.Although there was no significant difference between the levels of IgA anti-melanin autoantibodies in melanoma or vitiligo patients in comparison with controls, the enhanced concentrations of anti-melanin IgA autoantibodies were preferentially found in melanoma patients with metastatic disease. Significantly high percentage in the Fc alphaRI (CD89) positive cells was determined in melanoma patients (p < 0.002 and p < 0.008) in comparison to that found in healthy people or in patients with vitiligo, in the already mentioned order, pointing that IgA dependent cellular cytotoxicity is not important for the immune action against melanoma, even more that it is included in some immune suppression.Levels of IgG autoantibodies to mentioned antigens in melanoma patients although low were not significantly lower from controls. These findings analyzed together with the statistically significant low percentage of FcgammaRIII, (CD16) positive immunocompetent cells (p < 0.0007 and p < 0.003), which was found in patients with melanoma compared with healthy or vitiligo people respectively, and statistically significant low percentage of (CD16 + CD56+) natural killer (NK) cells (p < 0.005) found in melanoma patients in comparison to healthy controls pointed to the low probability for anti-melanoma IgG mediated, antibody mediated cellular cytotoxicity, (ADCC) and NK cytotoxicity. Moreover the ratio of the percentages of granulocytes and percentage of lymphocytes was statistically higher in patients with melanoma in relation to healthy people as well as to people with vitiligo (p < 0.0007 and p < 0.05 respectively).ConclusionAutoantibodies to tyrosinase and to melanin which are found even in healthy people, point that consummation of edible mushrooms that carry the antigen tyrosinase and melanin, could influence the humoral anti-melanoma immune response.Levels of different immunoglobulin classes of anti-melanin and anti-tyrosinase antibodies varied depending on the presence and the stage of studied diseases. Besides, the statistically enhanced ratio of the percentages of granulocytes and percentage of lymphocytes, together with statistically decreased percentage of NK cells is found in analyzed melanoma patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

Đorđić

Matić

Filipovic-Ljeskovic

et al. 2012

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…For the qualitative variables, e Fisher test was used, depending on t application. 9 Multilevel statistical modeling provides a practical means to include all repeated measures (ie, VASI) from all patients in a hierarchical analysis that accounts for data clustering on a per-patient basis according to time and NB-UV-B exposure. A further advantage of this model is that the effects of any irregularities in the times of VASI measurement (ie, missed or delayed monthly follow-up visits) are directly adjusted for by the model.…”

Section: Discussionmentioning

confidence: 99%

“…De etiología desconocida, Humphreys y Cox 8 lo describieron en 1988 en un paciente que fue tratado con tiabendazol, pero ningún caso posterior se ha relacionado con otro fármaco, sino que todos los descritos se han relacionado con antecedentes de herpes labial, como ocurre en nuestra paciente. En todos los casos descritos la histología confirma la presencia de un infiltrado linfocitario en la dermis alrededor de las células névicas, junto con degeneración y necrosis de los queratinocitos en la epidermis, sugestivo de EEM perinévico 4,[8][9][10] . La evolución de esta patología es idéntica a la acontecida en el EEM no perinévico, resolviéndose espontáneamente o con tratamiento corticoideo.…”

Section: Nevus Melanocíticounclassified

“…El melanoma es capaz de estimular el sistema inmune para generar una respuesta humoral y principalmente celular frente a antígenos presentes tanto en los melanocitos como en las células del melanoma. Este hecho tendría como consecuencia el rechazo tumoral, provocando una regresión del tumor primario y/o sus metástasis (aunque no suele ser suficiente para el control de la enfermedad), y secundariamente una despigmentación vitíligoide, focal o a distancia, que no presenta diferencias histológicas ni inmunohistoquímicas con respecto a la ocurrida en el vitíligo propiamente dicho (2,(8)(9)(10). Esta despigmentación está presente en el 2-7% de los pacientes con melanoma (frente al 1% de vitíligo en la población general), de forma espontánea o inducida tras inmunoterapia, y hasta en un 20% de los casos incluso antes del diagnóstico del melanoma.…”

Section: Regresión Y Despigmentación Vitiligoideunclassified

“…Varios estudios sugieren que el desarrollo de autoanticuerpos o manifestaciones clínicas de autoinmunidad, entre ellas vitíligo, durante el tratamiento adyuvante se ha relacionado con un beneficio significativo en la supervivencia (14,15). Hechos similares se han descrito con el uso de IFNβ (9). Por lo tanto, la autoinmunidad provocada por el tratamiento con IFN parece indicar un mejor pronóstico y debe alentar la continuación del mismo.…”

Section: Interferon (Ifn)unclassified

See 2 more Smart Citations

Caracterización Inmunofenotópica del sistema inmune en pacientes con vitíligo y/o halo nevus

Arriba¹

View full text Add to dashboard Cite

Cutaneous manifestations associated with melanoma

Vyas

Selph

Gerstenblith

2016

Seminars in Oncology

View full text Add to dashboard Cite

Complete remission of metastatic malignant melanoma after surgery in association with development of systemic vitiligo

Cited by 5 publications

References 6 publications

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

Caracterización Inmunofenotópica del sistema inmune en pacientes con vitíligo y/o halo nevus

Cutaneous manifestations associated with melanoma

Contact Info

Product

Resources

About